Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes (Q34186776)

31 July 2017

1 reference

title

Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes (English)

1 reference

31 July 2017

Owens RC Jr

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

21

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

301-319

1 reference

QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

How to measure the QT interval--what is normal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Measurement of the QT interval and the risk associated with QTc interval prolongation: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Measurement and interpretation of QT dispersion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Effects of antiarrhythmic drugs on QT interval dispersion--relationship to antiarrhythmic action and proarrhythmia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Effect of coronary ischemia on QT dispersion

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

A common polymorphism associated with antibiotic-induced cardiac arrhythmia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Long QT syndromes and torsade de pointes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Safety profile of grepafloxacin compared with other fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Experimental models of torsade de pointes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Accuracy of four automatic QT measurement techniques in cardiac patients and healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

QT dispersion: time for an obituary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

QT dispersion does not represent electrocardiographic interlead heterogeneity of ventricular repolarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Is QT interval prolongation harmful? A regulatory perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

A review of erythromycin-induced malignant tachyarrhythmia--torsade de pointes. A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

The macrolides: erythromycin, clarithromycin, and azithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Intersubject and dose-related variability after intravenous administration of erythromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Torsade de pointes. Mechanisms and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

QT prolongation and Torsades de Pointes associated with clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Torsade de pointes induced by cisapride/clarithromycin interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

The influence of cisapride and clarithromycin on QT intervals in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Azithromycin and terfenadine: lack of drug interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Torsade de pointes during administration of pentamidine isethionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Recurrent ventricular tachycardia due to pentamidine-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Ventricular tachycardia due to pentamidine isethionate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Pentamidine-induced torsade de pointes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Systemic antifungal agents. Drug interactions of clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Long QT syndrome and torsade de pointes in a patient receiving fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Fluoroquinolone toxicity profiles: a review focusing on newer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Comparative tolerability of the newer fluoroquinolone antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Safety profile of sparfloxacin, a new fluoroquinolone antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Safety of trovafloxacin in treatment of lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Safety profile of the quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Modulation of the proliferative response of murine thymocytes stimulated by IL-1, and enhancement of IL-1β secretion from mononuclear phagocytes by tetracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Pharmacokinetics of quinolones in renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

A structural basis for drug-induced long QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Structure-activity and structure-side-effect relationships for the quinolone antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

Use of terfenadine and contraindicated drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

The QT interval and torsade de pointes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

21 January 2018

Toxicity of quinolones

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.3.301.34206

10.1592/PHCO.21.3.301.34206

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference